New CenterWatch study finds major differences in performance and outlook between investigative sites by size, age and setting
Results of the 2012 CenterWatch Study of Global Investigative Sites released in today’s CenterWatch Monthly reveal wide differences in profits, growth and economic optimism between the largest and smallest sites, the youngest and oldest sites, and for-profit versus not-for-profit sites.
In its most extensive study of investigative site operations in a decade, CenterWatch surveyed 257 global sites about their finances, operations and outlook for economic recovery. The average site reported a rebound in operating conditions but concern about the stability of the clinical research sector. A complimentary sample of the summary report and data is available at www.centerwatch.com/promotions/sampledata.pdf.
While small sites (five or fewer employees) saw the strongest top-line revenue growth in 2011, up 15%, and the highest profit margin of all site groups, the largest sites are more poised for growth, with 63% reporting expansion plans in 2012, compared to only 36% of small sites.
Younger sites saw the fastest growth and are the most optimistic about the future. More than half of those in business for less than five years expect economic conditions to improve this year, while only 20% of sites with more than 21 years of experience share that optimism.
“Although it is common for pharmaceutical companies and contract research organizations to think of investigative sites as a homogeneous group,” said CenterWatch COO Joan Chambers, “CenterWatch research shows time and again that there are wide differences between investigative sites across a variety of characteristics including size, volume of activity, age, and clinical trial setting. The results of this CenterWatch study offer real insights into the unique operating needs of various types of investigative sites.”
In April, CenterWatch released part one of this study reporting on growth in clinical trial activity, staffing, patient volume and revenue.
Read an excerpt from this feature article, purchase a copy of the May issue or subscribe to The CenterWatch Monthly online at http://store.centerwatch.com, email email@example.com or call (617) 948-5100. New subscribers will receive the full summary report with 20 data and methodology charts.
Founded in 1994, CenterWatch is a trusted source for clinical trials information and analysis by research professionals and patients. CenterWatch provides a wide variety of information services including grant leads and actionable insights for investigative sites; business development leads and strategic news for sponsors and contract service providers; postings of industry-wide career opportunities; listings of clinical trials actively seeking patients; advertising and promotional opportunities; and proprietary business analysis, market and drug intelligence. Visit www.centerwatch.com.